Xenical Swedish Study May Provide Prospective Breast Cancer Risk Data
Executive Summary
A Phase III trial in Sweden may provide prospective data concerning breast cancer risk in women taking Roche's Xenical, FDA's Endocrinologic and Metabolic Drugs Advisory Committee suggested March 13.